Physician profile
Michael Shapiro
NPI 1306861604
$4,035.85
in general payments reported to CMS, 2019-2025
30 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $1,502 · 2021: $748 · 2022: $41.19 · 2023: $246 · 2024: $376 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $848.78 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.22 | 2019-2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $600.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $243.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $224.96 | 2019-2024 | Fasenra |
| Alexion Pharmaceuticals, INC. | $191.42 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $153.49 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $148.98 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $114.63 | 2019 | |
| Philips North America LLC | $107.21 | 2019-2025 | Vest Therapy Und |
| Janssen Pharmaceuticals, INC | $79.25 | 2020 | |
| Allergan, INC. | $66.68 | 2019 | |
| Genentech USA, INC. | $65.32 | 2019-2020 | |
| Kerecis Limited | $56.94 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Electromed, INC. | $52.84 | 2019-2024 | Smartvest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $52.21 | 2019-2024 | |
| Inogen, INC. | $48.14 | 2023 | Inogen |
| Merck Sharp & Dohme LLC | $37.92 | 2019-2025 | Zerbaxa |
| United Therapeutics Corporation | $36.59 | 2024 | Tyvaso |
| Grifols USA, LLC | $34.18 | 2020 | |
| Insmed, INC. | $31.94 | 2025 | Arikayce |
| Ani Pharmaceuticals, INC. | $26.64 | 2025 | Purified Cortrophin Gel |
| Pinnacle Biologics, INC | $24.10 | 2024 | Photofrin |
| Esperion Therapeutics, INC. | $23.96 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $20.90 | 2024 | Glassia |
| Mallinckrodt Enterprises LLC | $18.74 | 2019 | |
| Shire North American Group INC | $17.58 | 2019 | |
| Gilead Sciences, INC. | $17.06 | 2023 | Veklury |
| Amgen INC. | $15.85 | 2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.